Tonix Pharma Receives Official Minutes From Type C Meeting With FDA To Discuss Plans For Adaptive Phase 2 Field Study Of TNX-4800 To Prevent Lyme Disease In Adults In US
Alignment with FDA on key elements of the study design support planned start of the Phase 2 study in the first quarter of 2027Long-acting monoclonal antibody TNX-4800 is a rapidly acting alternative to vaccination
Tonix Pharma got the okay from the FDA to move forward with testing a new medicine that could help prevent Lyme disease. This is a good sign that the company's plan looks solid, though testing still takes a long time before we know if it really works.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.